FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): DURABLE REMISSIONS WITH FRONTLINE OBINUTUZUMAB (G) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE (G-FC) OR BENDAMUSTINE (G-B)
EHA Learning Center, Jennifer Brown, 181540
THE PROGNOSTIC SIGNIFICANCE OF CLL-IPI AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANT IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE MAYO CLINIC EXPERIENCE
EHA Learning Center, Theodora Anagnostou, 181541
IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL
EHA Learning Center, Sébastien Rinaldetti, 181542
HLA-G MOLECULES AND CLINICAL OUTCOME IN CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Giovanni Caocci, 181543
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
EHA Learning Center, Timothy Hughes, 181544
NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS
EHA Learning Center, Sudeep Pushpakom, 181545
EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Su Young Jung, 181546
A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL
EHA Learning Center, Georg-Nikolaus Franke, 181548
VALIDATION OF THE EUTOS LONG TERM SURVIVAL (ELTS) SCORE IN DUTCH CML-PATIENTS
EHA Learning Center, Inge , 181549
FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF FOLLOW-UP
EHA Learning Center, Hirohisa Nakamae, 181550
ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE
EHA Learning Center, Diana Passaro, 181551
BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS
EHA Learning Center, Richard Groen, 181552
MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS
EHA Learning Center, Cesar Nombela Arrieta, 181553
TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION
EHA Learning Center, Marvyn Koning, 181554
TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION
EHA Learning Center, Stephanie Solier, 181555
MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13
EHA Learning Center, Katia Beider, 181556
RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR
EHA Learning Center, Sorcha OByrne, 181557
HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS
EHA Learning Center, Miguel Ganuza Fernandez, 181558
A20 RESTRAINS THYMIC REGULATORY T CELL DEVELOPMENT
EHA Learning Center, Tobias Haas, 181559
THE TRANSCRIPTION FACTOR C/EBPG REGULATES MAST CELL DEVELOPMENT AND FUNCTION
EHA Learning Center, Miroslava Kardosova, 181560
TRANSCRIPTIONAL DIVERSITY AND DEVELOPMENTAL POTENTIAL OF EARLY HEMATOPOIETIC PROGENITORS REVEALED BY CELLULAR BARCODING AND TRANSCRIPTOME-WIDE PROFILING
EHA Learning Center, Diana Tronik-Le Roux, 181561
LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL) TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP (GHSG)
EHA Learning Center, Dennis A. Eichenauer, 181562
ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER NETWORK: A 10-YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR ABVD AND ESCALATED-BEACOPP TREATED PATIENTS AGED 16-59
EHA Learning Center, James , 181563
IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION
EHA Learning Center, Novella Pugliese, 181564
LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN'S LYMPHOMA (CHL) PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED KINGDOM
EHA Learning Center, Katherine Byrne, 181565
CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS.
EHA Learning Center, Hayder Saeed, 181566
THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. A NATIONWIDE POPULATION BASED ANALYSIS
EHA Learning Center, Panagiotis Tsirigotis, 181567
NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
EHA Learning Center, Burhan Ferhanoglu, 181568
GENOTYPING OF HODGKIN LYMPHOMA ON THE LIQUID BIOPSY
EHA Learning Center, Valeria Spina, 181569
FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN INDUCED CARDIOTOXICITY IN HODGKIN LYMPHOMA
EHA Learning Center, Eleonora Arboscello, 181570
ELEVATED SYSTEMIC HEME AND IRON LEVELS AS RISK FACTORS FOR VASCULAR DYSFUNCTION AND ATHEROSCLEROSIS: EVIDENCE FROM B-THALASSEMIA AND HEMOCHROMATOSIS COHORT STUDIES
EHA Learning Center, Francesca Vinchi, 181571
REAL-WORLD ADHERENCE TO IRON CHELATION THERAPY: COMPARING A FILM-COATED TABLET VERSUS DISPERSIBLE TABLET OF DEFERASIROX
EHA Learning Center, Qayyim Said, 181572
MEDIATION BY PATIENT-REPORTED OUTCOMES ON THE ASSOCIATION BETWEEN FILM-COATED VERSUS DISPERSIBLE FORMULATIONS OF DEFERASIROX AND SERUM FERRITIN REDUCTION: A POST HOC ANALYSIS OF THE ECLIPSE TRIAL
EHA Learning Center, Ali , 181573
ASSESSMENT OF THE PERFORMANCE OF A WIDELY AVAILABLE T2*/R2* LIVER IRON CONCENTRATION METHOD USED IN CLINICAL PRACTICE IN A POPULATION OF THALASSEMIA PATIENTS
EHA Learning Center, Tim St Pierre, 181574
SIMILAR TRENDS IN RENAL FUNCTION AS MEASURED BY SERUM CREATININE DURING LONG-TERM IRON CHELATION TREATMENT WITH OR WITHOUT DEFERASIROX IN PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS
EHA Learning Center, Raffaella Origa, 181575
WHEN IRON LEADS TO RED CELLS (AND VICE VERSA): A COMPREHENSIVE PHENOTYPE -TOWARDS NGS/WES PATHWAY FOR THE DIAGNOSIS OF RED CELL AND IRON DISORDERS
EHA Learning Center, Patricia Aguilar-Martinez, 181576
CHANGES IN LIVER IRON CONCENTRATION R2 MRI MEASUREMENT ACROSS DIFFERENT CHELATION REGIMENS IN PATIENTS WITH HEMATOLOGICAL DISORDERS: REAL-LIFE EXPERIENCE FROM LICNET
EHA Learning Center, Aurelio Maggio, 181577
IN UTERO IRON STATUS AND AUDITORY NEURAL MATURATION IN FULL TERM INFANTS BORN TO MOTHERS WITH IRON DEFICIENCY ANEMIA
EHA Learning Center, Rania El-Farrash, 181578
THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PEDIATRIC CANCER SURVIVORS
EHA Learning Center, Tim St. Pierre, 181579
DECREASED MCP-1 LEVELS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA: A CYTOKINE SIGNATURE OF IRON DEFICIENCY
EHA Learning Center, Graca Porto, 181580
FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE COMPLEX IN WOMEN WITH IRON DEFICIENCY ANEMIA - A RANDOMISED CONTROLLED TRIAL
EHA Learning Center, Garima Chaudhry, 181581
GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY
EHA Learning Center, Amit Sud, 181582
SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA
EHA Learning Center, Patricia Balsas, 181583
AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS
EHA Learning Center, Maria Del Pilar Dominguez Rodriguez, 181584
XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
EHA Learning Center, Marta Crespo, 181585
MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING.
EHA Learning Center, Yosaku Watatani, 181586
A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS
EHA Learning Center, Martí Duran-Ferrer, 181587
ACTIVATION OF RHOA-VAV1 SIGNALING AXIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
EHA Learning Center, Manabu Fujisawa, 181588
STAT3 IS CONSTITUTIVELY ACTIVATED AND CAN BE A THERAPEUTIC TARGET OF JAK INHIBITORS IN CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION
EHA Learning Center, Erika Onozawa, 181589
RECURRENT MUTATIONS IN MICRO-RNA BINDING SITES MAY BE POTENTIALLY RELEVANT IN FOLLICULAR LYMPHOMA
EHA Learning Center, Erika Larrea, 181590
CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL
EHA Learning Center, Simone Ferrero, 181591
A LOOKBACK AT VWD TYPE 2A AND 2M CLASSIFICATION IN A LARGE COMPREHENSIVE HAEMOPHILIA CENTRE.
EHA Learning Center, Sarah Jaafar, 181592
RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF DYSFIBRINOGENEMIA AND HYPODYSFIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS.
EHA Learning Center, Cristina Santoro, 181593
PREVALENCE OF GENETIC MARKERS OF OXIDATIVE STRESS IN PATIENTS WITH SEVERE HEMOPHILIA FROM NORTH-WESTERN RUSSIA
EHA Learning Center, Sergey Kapustin, 181595
THE ROLE OF DNA METHYLATION AND EXPRESSION OF MMP-2 AND MMP-9 IN PATHOGENESIS OF INTRACEREBRAL HEMORRHAGE IN CONGENITAL FACTOR XIII DEFICIENCY
EHA Learning Center, ali noroozi aghideh, 181596
GENETIC CONFIRMATION AND FINDING NOVEL MUTATIONS IN GLANZMANN THROMBASTHENIA AND VON WILLEBRAND DISEASE FAMILIES BY DIAGNOSTIC EXOME SEQUENCING
EHA Learning Center, Ye Jee Shim, 181597
HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Irina Zotova, 181598
AN ALGORITHM TO IDENTITY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA
EHA Learning Center, Aukje Kreuger, 181599
MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Masayuki SHISEKI, 181600
MOLECULAR MARKERS PREDICTING RESPONSE TO AZACITIDINE TREATMENT FOR MYELODYSPLASTIC SYNDROMES.
EHA Learning Center, Yasuhito Nannya, 181601
UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Guillermo Montalban-Bravo, 181602
AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF GESMD AND GFM REGISTRIES.
EHA Learning Center, Félix López Cadenas, 181603
Phase II Study OPN-305, a (TLR-2) Antibody, in patients with lower risk myelodysplastic syndromes with prior hypomethylating agent (HMA) therapy
EHA Learning Center, Guillermo Montalban-Bravo, 181604
IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS
EHA Learning Center, Félix López Cadenas, 181605
VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS): A PHASE 1/COHORT EXPANSION STUDY
EHA Learning Center, Meagan Jacoby, 181606
ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE
EHA Learning Center, Santiago Barrio, 181607
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA
EHA Learning Center, Matteo Marchesini, 181608
PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.
EHA Learning Center, Mattia D'Agostino, 181609
TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA
EHA Learning Center, Salomon Manier, 181610
DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS TO IMIDS
EHA Learning Center, Konstantinos Dimopoulos, 181611
MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANDIDATE ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA
EHA Learning Center, Raquel Ordoñez, 181612
CLINICAL IMPLICATIONS OF CLONAL CD34+ CELLS IN STEM CELL HARVEST FROM PATIENTS WITH PLASMA CELL DYSCRASIAS
EHA Learning Center, Sneha CHITRE, 181613
PATHOPHYSIOLOGICAL FUNCTIONS AND CLINICAL IMPACT OF THE NEW IMMUNORECEPTOR SLAMF3 IN MULTIPLE MYELOMA
EHA Learning Center, Mariko Ishibashi, 181614
TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE (ADC), STRO-001
EHA Learning Center, Arturo Molina, 181615
GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING
EHA Learning Center, Isabel Cuenca, 181616
IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY
EHA Learning Center, Sigrun Thorsteinsdottir, 181617
PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Moritz Binder, 181618
LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB
EHA Learning Center, Philip L. McCarthy, 181619
UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Roman Hajek, 181620
EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF POLLUX
EHA Learning Center, Meletios A. Dimopoulos, 181621
DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (≥75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES
EHA Learning Center, María-Victoria Mateos, 181622
ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL
EHA Learning Center, Heinz Ludwig, 181623
EVALUATION OF GROWTH DIFFERENTIATION FACTOR-1 (GDF15) AS A NEW BIOMARKER FOR RENAL OUTCOMES IN DIFFERENT COHORTS OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Efstathios Kastritis, 181624
AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ICD) IN TRANSPLANT-INELIGIBLE PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
EHA Learning Center, Meletios A Dimopoulos, 181625
THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE (MP) FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)
EHA Learning Center, Jesus F. San Miguel, 181626
FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB (MPV) IN PATIENTS ≥ 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY
EHA Learning Center, Sonja Zweegman, 181627
THE EUROPEAN MYELOMA NETWORK EMN09 STUDY: CARFILZOMIB, BENDAMUSTINE, AND DEXAMETHASONE (CBD) IS EFFICIENT AND SAFE IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA
EHA Learning Center, M. Gramatzki, 181628
CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP
EHA Learning Center, Ute Hegenbart, 181629
MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE (POM) PLUS LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)
EHA Learning Center, Pieter Sonneveld, 181630
PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B KEYNOTE-013 STUDY
EHA Learning Center, David Siegel, 181631
ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM.
EHA Learning Center, Zoe Van de Wyngaert, 181632
SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Jinchul Kim, 181633
A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK
EHA Learning Center, Ovini GAMAGE, 181634
SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES
EHA Learning Center, Thomas Dejoie, 181635
THE CONNECT MM REGISTRY: IMPACT OF THE CYTOGENETIC ABNORMALITY T(11;14) ON SURVIVAL OUTCOMES IN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Cristina J. Gasparetto, 181636
RAS-PATHWAY MUTATION PATTERNS DEFINE EPIGENETIC SUBCLASSES IN JUVENILE MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Daniel Lipka, 181637
CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY
EHA Learning Center, Barbara , 181638
MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM - UNCLASSIFIABLE (MDS/MPN-U)
EHA Learning Center, Prithviraj Bose, 181639
GENOME WIDE DNA METHYLATION PROFILING IS PREDICTIVE OF OUTCOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Elliot Stieglitz, 181640
LEUKEMIC TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS: IS NGS PROFILE THE BEST PROGNOSTIC BIOMARKER?
EHA Learning Center, Venton Geoffroy, 181641